| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 26 | 2018 | 69 | 4.780 |
Why?
|
| Uterine Cervical Neoplasms | 63 | 2017 | 300 | 4.490 |
Why?
|
| Uterine Neoplasms | 57 | 2021 | 99 | 3.470 |
Why?
|
| Carcinoma | 34 | 2016 | 215 | 3.220 |
Why?
|
| Ovarian Neoplasms | 48 | 2016 | 267 | 2.830 |
Why?
|
| Neoplasm Staging | 75 | 2018 | 800 | 1.960 |
Why?
|
| Adenocarcinoma | 49 | 2013 | 475 | 1.910 |
Why?
|
| Hysterectomy | 27 | 2017 | 64 | 1.870 |
Why?
|
| Carcinoma, Endometrioid | 10 | 2021 | 14 | 1.630 |
Why?
|
| Estrogen Replacement Therapy | 12 | 2009 | 38 | 1.630 |
Why?
|
| Genital Neoplasms, Female | 21 | 2020 | 38 | 1.520 |
Why?
|
| Lymph Nodes | 11 | 2017 | 258 | 1.520 |
Why?
|
| Lymph Node Excision | 18 | 2017 | 91 | 1.380 |
Why?
|
| Carcinoma, Squamous Cell | 30 | 2012 | 629 | 1.380 |
Why?
|
| Neoplasm Recurrence, Local | 37 | 2017 | 446 | 1.290 |
Why?
|
| Women's Health | 9 | 2009 | 148 | 1.190 |
Why?
|
| Female | 226 | 2021 | 38074 | 1.150 |
Why?
|
| Breast Neoplasms | 12 | 2011 | 1536 | 1.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2017 | 468 | 0.950 |
Why?
|
| Vulvar Neoplasms | 11 | 2006 | 24 | 0.850 |
Why?
|
| Prognosis | 52 | 2017 | 2093 | 0.830 |
Why?
|
| Humans | 224 | 2021 | 68618 | 0.830 |
Why?
|
| Uterine Cervical Dysplasia | 10 | 2006 | 44 | 0.820 |
Why?
|
| Vaginal Neoplasms | 6 | 2006 | 21 | 0.780 |
Why?
|
| Lymphatic Metastasis | 32 | 2016 | 274 | 0.770 |
Why?
|
| Middle Aged | 110 | 2021 | 21147 | 0.740 |
Why?
|
| Aged | 92 | 2021 | 14862 | 0.730 |
Why?
|
| Neoplasm Invasiveness | 22 | 2017 | 369 | 0.710 |
Why?
|
| Medical Records Systems, Computerized | 7 | 2006 | 130 | 0.650 |
Why?
|
| Adult | 93 | 2021 | 21403 | 0.580 |
Why?
|
| Tamoxifen | 5 | 2011 | 62 | 0.560 |
Why?
|
| Aged, 80 and over | 32 | 2021 | 4848 | 0.550 |
Why?
|
| Estrogens | 8 | 2005 | 173 | 0.540 |
Why?
|
| Neoadjuvant Therapy | 2 | 2016 | 104 | 0.540 |
Why?
|
| Survival Rate | 17 | 2016 | 1056 | 0.530 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2016 | 33 | 0.530 |
Why?
|
| Developing Countries | 2 | 2016 | 106 | 0.520 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2018 | 125 | 0.520 |
Why?
|
| Disease-Free Survival | 15 | 2017 | 349 | 0.500 |
Why?
|
| Biomarkers, Tumor | 4 | 2016 | 508 | 0.500 |
Why?
|
| Carcinoma in Situ | 7 | 2005 | 47 | 0.500 |
Why?
|
| Vaginal Smears | 11 | 2005 | 79 | 0.490 |
Why?
|
| Hormone Replacement Therapy | 3 | 2006 | 20 | 0.490 |
Why?
|
| Leiomyoma | 3 | 2011 | 28 | 0.480 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2005 | 46 | 0.480 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2005 | 52 | 0.470 |
Why?
|
| Papanicolaou Test | 6 | 2005 | 54 | 0.470 |
Why?
|
| Cystadenocarcinoma, Serous | 4 | 2016 | 14 | 0.460 |
Why?
|
| Combined Modality Therapy | 28 | 2018 | 951 | 0.450 |
Why?
|
| Receptors, Estrogen | 15 | 1993 | 142 | 0.420 |
Why?
|
| Age Distribution | 14 | 2006 | 320 | 0.420 |
Why?
|
| Carcinosarcoma | 3 | 2017 | 12 | 0.410 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2011 | 4 | 0.400 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 2008 | 16 | 0.370 |
Why?
|
| Receptors, Progesterone | 11 | 1993 | 57 | 0.370 |
Why?
|
| Phytoestrogens | 1 | 2009 | 5 | 0.350 |
Why?
|
| Reoperation | 11 | 2016 | 467 | 0.320 |
Why?
|
| Adenocarcinoma, Clear Cell | 4 | 2017 | 9 | 0.320 |
Why?
|
| Neoplasm Metastasis | 14 | 2016 | 306 | 0.310 |
Why?
|
| Menopause | 6 | 2006 | 47 | 0.300 |
Why?
|
| Gestational Trophoblastic Disease | 2 | 2006 | 3 | 0.300 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2020 | 37 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 2 | 2009 | 772 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2009 | 931 | 0.290 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2017 | 3 | 0.290 |
Why?
|
| Progestins | 3 | 2005 | 19 | 0.280 |
Why?
|
| Laparotomy | 5 | 1997 | 65 | 0.280 |
Why?
|
| Cryosurgery | 8 | 1991 | 53 | 0.270 |
Why?
|
| International Cooperation | 8 | 2006 | 88 | 0.270 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2005 | 8 | 0.260 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2005 | 7 | 0.260 |
Why?
|
| Risk Factors | 18 | 2017 | 5731 | 0.260 |
Why?
|
| Adolescent | 26 | 2006 | 8912 | 0.260 |
Why?
|
| Cisplatin | 11 | 2017 | 192 | 0.260 |
Why?
|
| Cervix Uteri | 6 | 2001 | 64 | 0.250 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2018 | 129 | 0.250 |
Why?
|
| Vagina | 2 | 2005 | 88 | 0.240 |
Why?
|
| Proportional Hazards Models | 11 | 2017 | 792 | 0.240 |
Why?
|
| Neoplasm Grading | 4 | 2017 | 111 | 0.240 |
Why?
|
| Lymphatic Vessels | 1 | 2004 | 5 | 0.230 |
Why?
|
| Pelvis | 6 | 1995 | 38 | 0.230 |
Why?
|
| Societies, Medical | 9 | 2006 | 403 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2016 | 536 | 0.220 |
Why?
|
| Thromboembolism | 4 | 1984 | 91 | 0.220 |
Why?
|
| Pulmonary Embolism | 9 | 1990 | 253 | 0.220 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 73 | 0.220 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2002 | 15 | 0.210 |
Why?
|
| Isoenzymes | 2 | 2003 | 308 | 0.210 |
Why?
|
| Ovariectomy | 4 | 2009 | 49 | 0.200 |
Why?
|
| Acridines | 1 | 2002 | 2 | 0.200 |
Why?
|
| Gynecology | 2 | 2014 | 46 | 0.200 |
Why?
|
| Clinical Trials as Topic | 12 | 2008 | 848 | 0.200 |
Why?
|
| Misonidazole | 2 | 1993 | 3 | 0.190 |
Why?
|
| Medical Oncology | 2 | 2014 | 110 | 0.190 |
Why?
|
| Chromium Compounds | 4 | 1987 | 6 | 0.190 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2001 | 64 | 0.190 |
Why?
|
| Interleukin-12 | 1 | 2001 | 75 | 0.190 |
Why?
|
| Hydroxyurea | 2 | 1993 | 57 | 0.190 |
Why?
|
| Survival Analysis | 8 | 2021 | 714 | 0.180 |
Why?
|
| Pyrazoles | 1 | 2002 | 190 | 0.180 |
Why?
|
| Mass Screening | 5 | 1995 | 843 | 0.170 |
Why?
|
| Antineoplastic Agents | 3 | 2002 | 1070 | 0.170 |
Why?
|
| Global Health | 7 | 2006 | 136 | 0.170 |
Why?
|
| Retrospective Studies | 16 | 2016 | 7277 | 0.170 |
Why?
|
| Thrombophlebitis | 6 | 1990 | 47 | 0.170 |
Why?
|
| Heparin | 7 | 1990 | 205 | 0.160 |
Why?
|
| Melanoma | 2 | 1999 | 335 | 0.160 |
Why?
|
| Peritoneal Neoplasms | 3 | 2015 | 23 | 0.160 |
Why?
|
| Contraindications | 4 | 2005 | 52 | 0.160 |
Why?
|
| Trophoblastic Neoplasms | 3 | 1999 | 4 | 0.160 |
Why?
|
| Phosphorus Radioisotopes | 4 | 1987 | 29 | 0.150 |
Why?
|
| Receptor, Notch2 | 1 | 2017 | 3 | 0.150 |
Why?
|
| Chromium | 4 | 1987 | 26 | 0.150 |
Why?
|
| Brachytherapy | 3 | 2016 | 79 | 0.150 |
Why?
|
| Phosphates | 4 | 1987 | 72 | 0.150 |
Why?
|
| Drug Administration Schedule | 6 | 2017 | 567 | 0.150 |
Why?
|
| Postoperative Complications | 16 | 1993 | 1615 | 0.150 |
Why?
|
| Bevacizumab | 1 | 2017 | 34 | 0.150 |
Why?
|
| Intestinal Obstruction | 2 | 1988 | 36 | 0.150 |
Why?
|
| Surgical Mesh | 2 | 1988 | 57 | 0.150 |
Why?
|
| Prospective Studies | 15 | 2021 | 3705 | 0.140 |
Why?
|
| gamma-Synuclein | 1 | 2016 | 1 | 0.140 |
Why?
|
| Cystadenocarcinoma, Papillary | 2 | 2008 | 6 | 0.140 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2016 | 3 | 0.140 |
Why?
|
| Laser Therapy | 5 | 1991 | 54 | 0.140 |
Why?
|
| Hospitals | 1 | 1999 | 265 | 0.140 |
Why?
|
| Propionibacterium acnes | 3 | 1983 | 10 | 0.140 |
Why?
|
| Organoplatinum Compounds | 2 | 2002 | 21 | 0.140 |
Why?
|
| Follow-Up Studies | 13 | 2017 | 3259 | 0.140 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 54 | 0.130 |
Why?
|
| Sterilization, Tubal | 1 | 2015 | 5 | 0.130 |
Why?
|
| Fallopian Tube Neoplasms | 2 | 2006 | 6 | 0.130 |
Why?
|
| Infusions, Intravenous | 3 | 2017 | 334 | 0.130 |
Why?
|
| Health Resources | 1 | 2016 | 76 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2005 | 99 | 0.130 |
Why?
|
| Decision Making | 1 | 1999 | 410 | 0.130 |
Why?
|
| Electrosurgery | 1 | 1994 | 15 | 0.120 |
Why?
|
| Patient Selection | 1 | 1999 | 592 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 240 | 0.120 |
Why?
|
| Cohort Studies | 5 | 2015 | 2358 | 0.120 |
Why?
|
| Drug Evaluation | 8 | 2001 | 47 | 0.120 |
Why?
|
| Sarcoma | 6 | 1998 | 70 | 0.120 |
Why?
|
| Predictive Value of Tests | 6 | 2017 | 1465 | 0.120 |
Why?
|
| History, 20th Century | 2 | 2020 | 248 | 0.110 |
Why?
|
| Pregnancy | 13 | 2008 | 2334 | 0.110 |
Why?
|
| Thrombosis | 2 | 1986 | 218 | 0.110 |
Why?
|
| Ascites | 2 | 1984 | 38 | 0.110 |
Why?
|
| Vulva | 2 | 1992 | 6 | 0.110 |
Why?
|
| Surgical Procedures, Operative | 2 | 1997 | 124 | 0.110 |
Why?
|
| RGS Proteins | 1 | 2013 | 22 | 0.110 |
Why?
|
| Pelvic Exenteration | 3 | 1989 | 3 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2017 | 447 | 0.100 |
Why?
|
| Risk | 6 | 2017 | 563 | 0.100 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 4 | 1986 | 15 | 0.100 |
Why?
|
| Carcinoma, Basosquamous | 1 | 1992 | 4 | 0.100 |
Why?
|
| Histones | 1 | 2013 | 111 | 0.100 |
Why?
|
| United States | 4 | 2017 | 7367 | 0.100 |
Why?
|
| Treatment Outcome | 5 | 2017 | 7029 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2013 | 193 | 0.100 |
Why?
|
| Polyglactin 910 | 2 | 1988 | 8 | 0.100 |
Why?
|
| Progesterone | 1 | 1992 | 115 | 0.100 |
Why?
|
| Radiation Injuries | 3 | 1990 | 97 | 0.100 |
Why?
|
| Urinary Catheterization | 2 | 1988 | 27 | 0.100 |
Why?
|
| Luteinizing Hormone | 1 | 1991 | 31 | 0.090 |
Why?
|
| BCG Vaccine | 1 | 1990 | 12 | 0.090 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1991 | 29 | 0.090 |
Why?
|
| Time Factors | 17 | 2017 | 4655 | 0.090 |
Why?
|
| Immunotherapy | 3 | 1983 | 215 | 0.090 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1991 | 52 | 0.090 |
Why?
|
| Polymers | 2 | 1994 | 244 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 2279 | 0.090 |
Why?
|
| Leiomyosarcoma | 3 | 1993 | 17 | 0.090 |
Why?
|
| Plant Preparations | 1 | 2009 | 18 | 0.090 |
Why?
|
| Odds Ratio | 3 | 2018 | 880 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2004 | 1046 | 0.080 |
Why?
|
| Random Allocation | 9 | 1990 | 442 | 0.080 |
Why?
|
| Peritoneal Cavity | 5 | 1987 | 25 | 0.080 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 1988 | 5 | 0.080 |
Why?
|
| Adenocarcinoma, Papillary | 2 | 1985 | 12 | 0.080 |
Why?
|
| Ureteral Obstruction | 1 | 1988 | 25 | 0.080 |
Why?
|
| Intestinal Diseases | 1 | 1988 | 25 | 0.080 |
Why?
|
| Palliative Care | 2 | 1988 | 271 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2008 | 113 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2008 | 238 | 0.070 |
Why?
|
| Pelvic Neoplasms | 3 | 1990 | 13 | 0.070 |
Why?
|
| Carcinoma, Papillary | 1 | 1987 | 35 | 0.070 |
Why?
|
| Dilatation and Curettage | 1 | 2006 | 5 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2003 | 1753 | 0.070 |
Why?
|
| Biopsy | 6 | 2001 | 540 | 0.070 |
Why?
|
| Dysgerminoma | 2 | 1984 | 9 | 0.070 |
Why?
|
| Paclitaxel | 2 | 2017 | 140 | 0.070 |
Why?
|
| Urinary Bladder | 1 | 1987 | 108 | 0.070 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 1986 | 15 | 0.070 |
Why?
|
| Leg | 3 | 1984 | 191 | 0.070 |
Why?
|
| Colposcopy | 4 | 2001 | 20 | 0.070 |
Why?
|
| Hemorrhage | 2 | 1984 | 328 | 0.060 |
Why?
|
| Premedication | 2 | 1983 | 49 | 0.060 |
Why?
|
| Interferon Type I | 1 | 1985 | 32 | 0.060 |
Why?
|
| Ascitic Fluid | 2 | 1981 | 22 | 0.060 |
Why?
|
| Progesterone-Binding Globulin | 2 | 1981 | 2 | 0.060 |
Why?
|
| Estrogens, Conjugated (USP) | 3 | 1999 | 12 | 0.060 |
Why?
|
| Catheterization | 1 | 1986 | 209 | 0.060 |
Why?
|
| Doxorubicin | 5 | 1990 | 231 | 0.060 |
Why?
|
| Indium | 1 | 1984 | 2 | 0.060 |
Why?
|
| Etoposide | 3 | 1996 | 64 | 0.060 |
Why?
|
| Phosphonoacetic Acid | 1 | 1984 | 5 | 0.060 |
Why?
|
| Organophosphorus Compounds | 1 | 1984 | 13 | 0.060 |
Why?
|
| Radioisotopes | 1 | 1984 | 40 | 0.060 |
Why?
|
| Research Design | 2 | 1999 | 729 | 0.060 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 1984 | 17 | 0.060 |
Why?
|
| Aspartic Acid | 1 | 1984 | 65 | 0.060 |
Why?
|
| Cytological Techniques | 1 | 1984 | 23 | 0.060 |
Why?
|
| Leukopenia | 5 | 1996 | 23 | 0.060 |
Why?
|
| Recurrence | 4 | 1993 | 948 | 0.050 |
Why?
|
| Blood Platelets | 1 | 1984 | 284 | 0.050 |
Why?
|
| Postmenopause | 1 | 2003 | 93 | 0.050 |
Why?
|
| Vincristine | 3 | 2007 | 44 | 0.050 |
Why?
|
| Incidence | 2 | 1998 | 1603 | 0.050 |
Why?
|
| Pleural Effusion | 1 | 1983 | 74 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2003 | 282 | 0.050 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 3 | 1991 | 14 | 0.050 |
Why?
|
| Sutures | 2 | 1994 | 32 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2003 | 160 | 0.050 |
Why?
|
| Pilot Projects | 3 | 1995 | 1342 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 507 | 0.050 |
Why?
|
| Cefamandole | 1 | 1982 | 5 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2003 | 125 | 0.050 |
Why?
|
| Lymphatic Diseases | 1 | 1982 | 27 | 0.050 |
Why?
|
| Alpha-Globulins | 1 | 1981 | 18 | 0.050 |
Why?
|
| Cephalosporins | 1 | 1982 | 59 | 0.050 |
Why?
|
| Electrocoagulation | 4 | 1983 | 35 | 0.050 |
Why?
|
| Terminology as Topic | 2 | 1999 | 141 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2003 | 358 | 0.050 |
Why?
|
| Postoperative Care | 3 | 1995 | 163 | 0.050 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 1981 | 33 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2005 | 1553 | 0.050 |
Why?
|
| Cysts | 1 | 1982 | 70 | 0.050 |
Why?
|
| Antigen-Antibody Complex | 1 | 1982 | 175 | 0.050 |
Why?
|
| Thrombocytopenia | 4 | 1996 | 122 | 0.050 |
Why?
|
| Anticoagulants | 1 | 1983 | 356 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2003 | 402 | 0.050 |
Why?
|
| Age Factors | 5 | 2015 | 1864 | 0.050 |
Why?
|
| Pregnancy Complications | 4 | 1973 | 286 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 1982 | 168 | 0.050 |
Why?
|
| Logistic Models | 2 | 2015 | 1420 | 0.040 |
Why?
|
| Preoperative Care | 4 | 1985 | 275 | 0.040 |
Why?
|
| History, 19th Century | 1 | 2020 | 95 | 0.040 |
Why?
|
| Medroxyprogesterone | 1 | 1979 | 3 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2020 | 127 | 0.040 |
Why?
|
| Child | 4 | 1999 | 6405 | 0.040 |
Why?
|
| Endometrium | 6 | 1991 | 31 | 0.040 |
Why?
|
| Cyclophosphamide | 5 | 1995 | 129 | 0.040 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 1999 | 9 | 0.040 |
Why?
|
| Sampling Studies | 1 | 1999 | 80 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2001 | 742 | 0.040 |
Why?
|
| Melphalan | 1 | 1979 | 15 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 1998 | 57 | 0.040 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1978 | 12 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2003 | 617 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 1999 | 649 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 1981 | 597 | 0.040 |
Why?
|
| Conization | 1 | 1998 | 3 | 0.040 |
Why?
|
| DNA Polymerase II | 1 | 2017 | 5 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2017 | 7 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2017 | 25 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2017 | 39 | 0.040 |
Why?
|
| Absorption | 3 | 1991 | 49 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2017 | 42 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2017 | 41 | 0.040 |
Why?
|
| Informed Consent | 1 | 1999 | 127 | 0.040 |
Why?
|
| Topotecan | 1 | 2017 | 17 | 0.040 |
Why?
|
| Data Collection | 1 | 1999 | 420 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 1174 | 0.040 |
Why?
|
| Social Class | 1 | 2017 | 127 | 0.040 |
Why?
|
| Survivors | 1 | 1999 | 256 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 33 | 0.040 |
Why?
|
| Disease Progression | 2 | 2017 | 1038 | 0.030 |
Why?
|
| Precancerous Conditions | 2 | 1975 | 74 | 0.030 |
Why?
|
| Suture Techniques | 2 | 1994 | 75 | 0.030 |
Why?
|
| Cause of Death | 2 | 1995 | 241 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 231 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 2800 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 1999 | 425 | 0.030 |
Why?
|
| Meninges | 1 | 1975 | 7 | 0.030 |
Why?
|
| Remission Induction | 2 | 1996 | 111 | 0.030 |
Why?
|
| Paget Disease, Extramammary | 1 | 1975 | 5 | 0.030 |
Why?
|
| Databases, Factual | 1 | 1998 | 622 | 0.030 |
Why?
|
| Fallopian Tubes | 2 | 1992 | 11 | 0.030 |
Why?
|
| CA-125 Antigen | 1 | 1995 | 5 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 3 | 1984 | 219 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 1995 | 21 | 0.030 |
Why?
|
| Estradiol | 2 | 1991 | 176 | 0.030 |
Why?
|
| Honduras | 1 | 2014 | 21 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1985 | 2324 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2014 | 78 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 378 | 0.030 |
Why?
|
| Histocytochemistry | 2 | 2012 | 149 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2017 | 326 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 1984 | 166 | 0.030 |
Why?
|
| Gene Expression | 1 | 2016 | 770 | 0.030 |
Why?
|
| Cytodiagnosis | 2 | 1986 | 20 | 0.030 |
Why?
|
| Life Tables | 1 | 1993 | 29 | 0.030 |
Why?
|
| Body Weight | 2 | 2008 | 554 | 0.030 |
Why?
|
| Veins | 2 | 1984 | 68 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 786 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 3 | 1989 | 107 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 756 | 0.030 |
Why?
|
| Acetylation | 1 | 2013 | 94 | 0.030 |
Why?
|
| Parity | 4 | 1980 | 71 | 0.030 |
Why?
|
| Osteoporosis | 2 | 1992 | 88 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 627 | 0.030 |
Why?
|
| Obesity | 2 | 2015 | 1076 | 0.030 |
Why?
|
| Inguinal Canal | 1 | 1992 | 5 | 0.030 |
Why?
|
| Mutation | 1 | 2017 | 1213 | 0.030 |
Why?
|
| Risk Assessment | 1 | 1998 | 2007 | 0.030 |
Why?
|
| Neoplasms | 1 | 2003 | 1667 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 1991 | 504 | 0.030 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1972 | 34 | 0.030 |
Why?
|
| Microscopy | 1 | 2012 | 64 | 0.030 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 1991 | 9 | 0.020 |
Why?
|
| Iodine Radioisotopes | 3 | 1990 | 119 | 0.020 |
Why?
|
| Fasciotomy | 1 | 1991 | 12 | 0.020 |
Why?
|
| Dehydroepiandrosterone | 1 | 1991 | 29 | 0.020 |
Why?
|
| Androgens | 1 | 1991 | 41 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1993 | 737 | 0.020 |
Why?
|
| Stroke | 1 | 2003 | 2163 | 0.020 |
Why?
|
| Abdomen | 1 | 1991 | 80 | 0.020 |
Why?
|
| Lymphedema | 1 | 1990 | 6 | 0.020 |
Why?
|
| Testosterone | 1 | 1991 | 96 | 0.020 |
Why?
|
| Infusions, Parenteral | 2 | 1981 | 47 | 0.020 |
Why?
|
| Cytoplasm | 3 | 1985 | 155 | 0.020 |
Why?
|
| Ovary | 1 | 1991 | 99 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 3 | 1989 | 511 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 1991 | 202 | 0.020 |
Why?
|
| Methods | 4 | 1987 | 156 | 0.020 |
Why?
|
| Administration, Oral | 3 | 1996 | 411 | 0.020 |
Why?
|
| Carboplatin | 1 | 1989 | 59 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 1991 | 307 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2014 | 596 | 0.020 |
Why?
|
| Warfarin | 2 | 1983 | 93 | 0.020 |
Why?
|
| Mesonephroma | 2 | 1985 | 3 | 0.020 |
Why?
|
| Urinary Diversion | 1 | 1988 | 16 | 0.020 |
Why?
|
| Cautery | 2 | 1981 | 5 | 0.020 |
Why?
|
| Chordoma | 1 | 1967 | 9 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 1851 | 0.020 |
Why?
|
| Platelet Count | 2 | 1985 | 100 | 0.020 |
Why?
|
| Back Pain | 1 | 1967 | 30 | 0.020 |
Why?
|
| Retroperitoneal Space | 1 | 1987 | 7 | 0.020 |
Why?
|
| Intestine, Small | 1 | 1988 | 89 | 0.020 |
Why?
|
| Blood Cell Count | 2 | 1984 | 35 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 1987 | 23 | 0.020 |
Why?
|
| Uterus | 1 | 1987 | 77 | 0.020 |
Why?
|
| Urination Disorders | 1 | 1987 | 20 | 0.020 |
Why?
|
| Aging | 1 | 1993 | 911 | 0.020 |
Why?
|
| Fetal Diseases | 2 | 1966 | 64 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 1851 | 0.020 |
Why?
|
| Aorta | 2 | 1985 | 316 | 0.020 |
Why?
|
| Endometriosis | 2 | 1991 | 56 | 0.020 |
Why?
|
| Erythroblastosis, Fetal | 1 | 1966 | 3 | 0.020 |
Why?
|
| Cardiovascular Diseases | 2 | 1992 | 940 | 0.020 |
Why?
|
| Mediastinal Neoplasms | 1 | 1986 | 27 | 0.020 |
Why?
|
| Subclavian Vein | 1 | 1986 | 17 | 0.020 |
Why?
|
| Nutritional Status | 1 | 1987 | 112 | 0.020 |
Why?
|
| Vena Cava, Superior | 1 | 1986 | 41 | 0.020 |
Why?
|
| Erythrocytes | 1 | 1966 | 137 | 0.020 |
Why?
|
| Specimen Handling | 1 | 1985 | 47 | 0.020 |
Why?
|
| Radiotherapy | 1 | 1985 | 86 | 0.020 |
Why?
|
| Vomiting | 4 | 1989 | 56 | 0.020 |
Why?
|
| Mitotic Index | 1 | 1985 | 14 | 0.020 |
Why?
|
| Ilium | 1 | 1985 | 16 | 0.020 |
Why?
|
| Epithelium | 2 | 1990 | 172 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 1985 | 63 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 1985 | 95 | 0.020 |
Why?
|
| Staining and Labeling | 2 | 1981 | 144 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 1984 | 57 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 1984 | 87 | 0.020 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1984 | 50 | 0.020 |
Why?
|
| Fever | 1 | 1985 | 96 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 1966 | 205 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1985 | 191 | 0.010 |
Why?
|
| Ileum | 1 | 1984 | 28 | 0.010 |
Why?
|
| Fatigue | 1 | 1985 | 132 | 0.010 |
Why?
|
| Intestinal Absorption | 1 | 1984 | 41 | 0.010 |
Why?
|
| Comorbidity | 1 | 2008 | 1426 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 1987 | 955 | 0.010 |
Why?
|
| Maytansine | 1 | 1983 | 1 | 0.010 |
Why?
|
| Oxazines | 1 | 1983 | 10 | 0.010 |
Why?
|
| Dacarbazine | 1 | 1983 | 32 | 0.010 |
Why?
|
| Clothing | 1 | 1983 | 7 | 0.010 |
Why?
|
| Anemia | 1 | 1984 | 104 | 0.010 |
Why?
|
| Skin Diseases | 1 | 1984 | 122 | 0.010 |
Why?
|
| Cervix Mucus | 2 | 1980 | 8 | 0.010 |
Why?
|
| Fractional Precipitation | 1 | 1982 | 2 | 0.010 |
Why?
|
| Lymph | 1 | 1982 | 8 | 0.010 |
Why?
|
| Thermoluminescent Dosimetry | 1 | 1981 | 3 | 0.010 |
Why?
|
| Suspensions | 1 | 1981 | 11 | 0.010 |
Why?
|
| Nausea | 3 | 1989 | 47 | 0.010 |
Why?
|
| Autoradiography | 1 | 1981 | 94 | 0.010 |
Why?
|
| Remission, Spontaneous | 2 | 1979 | 25 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1981 | 282 | 0.010 |
Why?
|
| Radiometry | 1 | 1981 | 64 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 1982 | 149 | 0.010 |
Why?
|
| Cystadenocarcinoma | 1 | 1980 | 2 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 5717 | 0.010 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1980 | 18 | 0.010 |
Why?
|
| Dogs | 1 | 1981 | 490 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1980 | 36 | 0.010 |
Why?
|
| Dextrans | 1 | 1980 | 33 | 0.010 |
Why?
|
| Podophyllotoxin | 1 | 1979 | 5 | 0.010 |
Why?
|
| Kinetics | 1 | 1981 | 1047 | 0.010 |
Why?
|
| Carcinogens | 1 | 1980 | 86 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1979 | 44 | 0.010 |
Why?
|
| Charcoal | 1 | 1980 | 37 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1979 | 8 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1982 | 481 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 1985 | 1173 | 0.010 |
Why?
|
| World Health Organization | 1 | 1999 | 53 | 0.010 |
Why?
|
| Therapeutic Irrigation | 2 | 1986 | 63 | 0.010 |
Why?
|
| Hypertension | 1 | 2008 | 1535 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 1980 | 183 | 0.010 |
Why?
|
| Body Temperature | 1 | 1978 | 116 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1982 | 1738 | 0.010 |
Why?
|
| Methotrexate | 2 | 1975 | 91 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 1980 | 340 | 0.010 |
Why?
|
| Fibrinogen | 2 | 1990 | 87 | 0.010 |
Why?
|
| Protein Binding | 1 | 1980 | 1027 | 0.010 |
Why?
|
| Urologic Diseases | 2 | 1989 | 11 | 0.010 |
Why?
|
| Tetracycline | 1 | 1973 | 29 | 0.010 |
Why?
|
| Intrauterine Devices | 1 | 1973 | 15 | 0.010 |
Why?
|
| Wilms Tumor | 1 | 1993 | 47 | 0.010 |
Why?
|
| Urography | 1 | 1972 | 21 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1978 | 1451 | 0.010 |
Why?
|
| Urine | 1 | 1972 | 47 | 0.010 |
Why?
|
| Prothrombin Time | 1 | 1972 | 24 | 0.010 |
Why?
|
| Mesenchymoma | 1 | 1972 | 4 | 0.010 |
Why?
|
| Fetal Death | 1 | 1972 | 49 | 0.010 |
Why?
|
| Ligation | 1 | 1972 | 83 | 0.010 |
Why?
|
| GPI-Linked Proteins | 1 | 1991 | 27 | 0.010 |
Why?
|
| Granulosa Cell Tumor | 1 | 1971 | 3 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1991 | 71 | 0.010 |
Why?
|
| Mucin-1 | 1 | 1991 | 35 | 0.010 |
Why?
|
| Cystadenoma | 1 | 1971 | 10 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 1991 | 132 | 0.010 |
Why?
|
| Equipment Safety | 1 | 1991 | 50 | 0.010 |
Why?
|
| Dactinomycin | 2 | 1985 | 31 | 0.010 |
Why?
|
| Efficiency | 1 | 1991 | 49 | 0.010 |
Why?
|
| Immunochemistry | 1 | 1990 | 17 | 0.010 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 1990 | 9 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1991 | 238 | 0.010 |
Why?
|
| Genital Diseases, Female | 1 | 1989 | 23 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1991 | 453 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1991 | 370 | 0.010 |
Why?
|
| Wound Healing | 1 | 1991 | 260 | 0.010 |
Why?
|
| North Carolina | 2 | 1979 | 224 | 0.000 |
Why?
|
| Animals | 2 | 1984 | 20881 | 0.000 |
Why?
|
| Hip | 1 | 1967 | 19 | 0.000 |
Why?
|
| Immunoenzyme Techniques | 1 | 1987 | 196 | 0.000 |
Why?
|
| Myometrium | 1 | 1986 | 5 | 0.000 |
Why?
|
| Hematologic Diseases | 1 | 1986 | 20 | 0.000 |
Why?
|
| Chromium Isotopes | 1 | 1966 | 2 | 0.000 |
Why?
|
| Blood Transfusion, Intrauterine | 1 | 1966 | 2 | 0.000 |
Why?
|
| Sex Determination Analysis | 1 | 1966 | 3 | 0.000 |
Why?
|
| Chromosomes | 1 | 1966 | 17 | 0.000 |
Why?
|
| Kidney Diseases | 1 | 1989 | 307 | 0.000 |
Why?
|
| Amniotic Fluid | 1 | 1966 | 30 | 0.000 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1966 | 57 | 0.000 |
Why?
|
| Radiography | 1 | 1987 | 572 | 0.000 |
Why?
|
| Frozen Sections | 1 | 1985 | 14 | 0.000 |
Why?
|
| Male | 2 | 1995 | 37321 | 0.000 |
Why?
|
| Hyperplasia | 1 | 1985 | 89 | 0.000 |
Why?
|
| Injections, Intraperitoneal | 1 | 1985 | 89 | 0.000 |
Why?
|
| Teratoma | 1 | 1985 | 22 | 0.000 |
Why?
|
| Cytosol | 1 | 1985 | 123 | 0.000 |
Why?
|
| Catheters, Indwelling | 1 | 1985 | 72 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1985 | 94 | 0.000 |
Why?
|
| Bacterial Vaccines | 1 | 1984 | 32 | 0.000 |
Why?
|
| Plethysmography, Impedance | 1 | 1984 | 17 | 0.000 |
Why?
|
| Neoplasm Transplantation | 1 | 1984 | 160 | 0.000 |
Why?
|
| Phlebography | 1 | 1984 | 31 | 0.000 |
Why?
|
| Pain | 1 | 1967 | 472 | 0.000 |
Why?
|
| Mice, Nude | 1 | 1984 | 294 | 0.000 |
Why?
|
| Intraoperative Care | 1 | 1984 | 91 | 0.000 |
Why?
|
| Pressure | 1 | 1984 | 252 | 0.000 |
Why?
|
| Probability | 1 | 1983 | 245 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1966 | 2455 | 0.000 |
Why?
|
| Digestive System | 1 | 1979 | 35 | 0.000 |
Why?
|
| Statistics as Topic | 1 | 1980 | 219 | 0.000 |
Why?
|
| Diagnostic Errors | 1 | 1980 | 100 | 0.000 |
Why?
|
| Castration | 1 | 1979 | 13 | 0.000 |
Why?
|
| Endocrine System Diseases | 1 | 1979 | 11 | 0.000 |
Why?
|
| Turner Syndrome | 1 | 1979 | 10 | 0.000 |
Why?
|
| Hypogonadism | 1 | 1979 | 9 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1979 | 168 | 0.000 |
Why?
|
| Fractures, Bone | 1 | 1979 | 132 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1979 | 1034 | 0.000 |
Why?
|
| Suppositories | 1 | 1973 | 2 | 0.000 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 1973 | 3 | 0.000 |
Why?
|
| Mental Disorders | 1 | 1979 | 659 | 0.000 |
Why?
|
| Placebos | 1 | 1973 | 195 | 0.000 |
Why?
|
| Hydatidiform Mole, Invasive | 1 | 1973 | 1 | 0.000 |
Why?
|
| Choriocarcinoma | 1 | 1973 | 7 | 0.000 |
Why?
|
| Hydatidiform Mole | 1 | 1973 | 3 | 0.000 |
Why?
|
| Chorionic Gonadotropin | 1 | 1973 | 7 | 0.000 |
Why?
|
| Chlorambucil | 1 | 1973 | 17 | 0.000 |
Why?
|
| Mice | 1 | 1984 | 8474 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1973 | 371 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1973 | 334 | 0.000 |
Why?
|
| Chromosome Disorders | 1 | 1966 | 31 | 0.000 |
Why?
|
| Chromosome Aberrations | 1 | 1966 | 86 | 0.000 |
Why?
|